Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 431

Results For "NAL"

6624 News Found

19 crore AB-PMJAY cards created; 3.8 crore beneficiaries avails free benefit
Policy | September 24, 2022

19 crore AB-PMJAY cards created; 3.8 crore beneficiaries avails free benefit

AB PMJAY has been successful in providing quality health services to the beneficiaries who come from weak financial backgrounds


Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP
Drug Approval | September 23, 2022

Lupin receives approval from US FDA for Diclofenac Sodium Topical Solution USP

Diclofenac Sodium Topical Solution USP, 2% w/w (RLD Pennsaid) had estimated annual sales of US $484 million in the US


Shilpa Medicare Hyderabad facility receives US FDA clearance
News | September 23, 2022

Shilpa Medicare Hyderabad facility receives US FDA clearance

The facility is identified as a testing laboratory in numerous ANDAs filed by Shilpa Medicare Limited and its agreed parties


Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer
Drug Approval | September 23, 2022

Lynparza approved in China as first-line maintenance treatment with Bevacizumab for HRD- positive advanced ovarian cancer

One in two women with advanced ovarian cancer has an HRD-positive tumor


KDAH receives SMART ICU certification after pandemic
News | September 23, 2022

KDAH receives SMART ICU certification after pandemic

Kokilaben Hospital is also the first hospital in Navi Mumbai to receive the SMART ICU certification


Aster Pharmacy forays into Bangladesh
Healthcare | September 22, 2022

Aster Pharmacy forays into Bangladesh

Aster Pharmacy will be operated by GD Assist Limited in Bangladesh.


Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners
Opinion | September 22, 2022

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.


Merck to initiate new Phase 3 clinical program for treatment of HIV-1 Infection
Clinical Trials | September 21, 2022

Merck to initiate new Phase 3 clinical program for treatment of HIV-1 Infection

Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir


Azelis expands pharmaceutical offerings with Clariant
News | September 21, 2022

Azelis expands pharmaceutical offerings with Clariant

Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.


Medical devices market in Singapore to reach $3.5 billion in 2022, forecasts GlobalData
News | September 21, 2022

Medical devices market in Singapore to reach $3.5 billion in 2022, forecasts GlobalData

Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments